You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ERK

Showing 1 - 25 of 467
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

Recruiting
  • Cancer
  • +6 more
  • Indianapolis, Indiana
    Indiana University Hospital / IU Simon Cancer Center
Jan 12, 2023

CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

Terminated
Has Results
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 30, 2022

Low-grade Glioma, Plexiform Neurofibroma, CNS Glioma Trial in Canada (Trametinib)

Active, not recruiting
  • Low-grade Glioma
  • +2 more
  • Calgary, Alberta, Canada
  • +6 more
Oct 25, 2022

Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis Trial in United States (procedure, drug,

Not yet recruiting
  • Colorectal Adenomatous Polyp
  • +3 more
  • Biopsy
  • +5 more
  • Ann Arbor, Michigan
  • +4 more
Jan 3, 2023

Acute Myeloid Leukemia Trial in Boston (LY3214996)

Recruiting
  • Acute Myeloid Leukemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 6, 2022

Triple Negative Breast Cancer Trial in Madison (Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet)

Terminated
Has Results
  • Triple Negative Breast Cancer
  • Akt/ERK Inhibitor ONC201
  • Methionine-Restricted Diet
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Feb 11, 2022

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +11 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Mar 22, 2022

Pancreatic Cancer, Colorectal Cancer, NSCLC Trial in Amsterdam (RMC-4630, LY3214996)

Not yet recruiting
  • Pancreatic Cancer
  • +3 more
  • (no location specified)
Mar 9, 2022

Pancreatic Cancer, Advanced Cancer Trial in Boston, Chapel Hill (Hydroxychloroquine Sulfate, LY3214996)

Recruiting
  • Pancreatic Cancer
  • Advanced Cancer
  • Boston, Massachusetts
  • +2 more
Apr 6, 2022

Glioblastoma, GBM, Glioma Trial in Chandler, Phoenix, Scottsdale (Abemaciclib, LY3214996)

Recruiting
  • Glioblastoma
  • +2 more
  • Chandler, Arizona
  • +2 more
Mar 10, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Triple Negative Breast Cancer Trial in Lleida, Madrid, Valencia (Combination, Palbociclib + Binimetinib)

Recruiting
  • Triple Negative Breast Cancer
  • Combination, Palbociclib + Binimetinib
  • Lleida, Spain
  • +7 more
Sep 1, 2021

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston

Recruiting
  • Metastatic Colon Adenocarcinoma
  • +30 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2022

Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer Trial in United States (Ulixertinib (BVD-523))

Available
  • Pancreatic Cancer
  • +20 more
  • Ulixertinib (BVD-523)
  • Birmingham, Alabama
  • +25 more
Nov 4, 2022

Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma Trial in Los Angeles (drug, radiation,

Withdrawn
  • Recurrent Glioblastoma
  • +3 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
May 10, 2021

Advanced Cancer, Metastatic Melanoma, Metastatic NSCLC Trial in Worldwide (LY3214996, Midazolam, Abemaciclib)

Active, not recruiting
  • Advanced Cancer
  • +3 more
  • Washington, District of Columbia
  • +12 more
Sep 2, 2021

Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma Trial (Ibrutinib, LY3214996)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • +3 more
  • (no location specified)
Feb 3, 2020

Epidermal Nevi, Nevus Sebaceus Trial in Redwood City (NFX-179 Gel 1.50%)

Not yet recruiting
  • Epidermal Nevi
  • Nevus Sebaceus
  • NFX-179 Gel 1.50%
  • Redwood City, California
    Stanford University
Mar 22, 2022

Tumor, Solid, Pancreatic Cancer Trial in Chapel Hill (Ulixertinib, Palbociclib)

Recruiting
  • Tumor, Solid
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 30, 2022

Melanoma, Solid Tumor Trial in Korea, Republic of, Spain, United States (DAY101, Pimasertib Hydrochloride)

Recruiting
  • Melanoma
  • Solid Tumor
  • Los Angeles, California
  • +13 more
Jul 27, 2022

Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor Trial (drug, procedure, biological)

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • Locally Advanced Malignant Solid Neoplasm
  • (no location specified)
Dec 2, 2022

Tumor, Solid, Gastrointestinal Cancer Trial in San Francisco, Ann Arbor (Ulixertinib, Hydroxychloroquine)

Recruiting
  • Tumor, Solid
  • Gastrointestinal Cancer
  • Tucson, Arizona
  • +7 more
Jan 13, 2023

Solid Tumor, Hematological Malignancy Trial in Australia (ATG-017)

Recruiting
  • Solid Tumor
  • Hematological Malignancy
  • East Melbourne, Victoria, Australia
  • +4 more
Jan 11, 2023

Tumor Metastasis Trial in Australia, United States (CC-90003)

Terminated
  • Neoplasm Metastasis
  • Los Angeles, California
  • +4 more
Nov 14, 2019

Lymphangioleiomyomatosis Trial in Milan (Nintedanib)

Completed
  • Lymphangioleiomyomatosis
  • Milan, Italy
    Pneumology unit
Sep 26, 2022